Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.

A Tale of Two Biotechs: Amgen Inc. vs. Merus N.V.

In the ever-evolving world of biotechnology, understanding the financial dynamics of industry giants like Amgen Inc. and emerging players such as Merus N.V. is crucial. Over the past decade, Amgen's Selling, General, and Administrative (SG&A) expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023, a 31% rise from 2014. This reflects Amgen's expansive operational strategies and market dominance.

Conversely, Merus N.V., a smaller biotech firm, has seen its SG&A expenses grow from a modest $3.9 million in 2014 to nearly $60 million in 2023, marking a staggering 1,438% increase. This surge underscores Merus's aggressive growth and investment in its operational infrastructure.

These contrasting trajectories highlight the diverse strategies within the biotech sector, where established firms focus on sustaining growth, while newcomers invest heavily to carve out their niche.